ReviewExperimental dermatology2026
mRNA Therapeutics for Skin Rejuvenation: From Aging Atlases to Clinical Translation.
Review in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Skin aging is a multifactorial process characterized by the progressive decline of tissue structure, function and regenerative capacity. Although numerous interventions have been developed to improve the clinical manifestations of aging, most primarily alleviate downstream consequences rather than directly targeting the molecular mechanisms underlying tissue deterioration. Recent advances in single-cell and spatial transcriptomic technologies have fundamentally transformed our understanding of skin aging by identifying cell type-specific transcriptional programmes and uncovering novel regulators of epidermal homeostasis, dermal remodelling and intercellular communication. These high-resolution atlases have generated an expanding repertoire of candidate rejuvenation targets, many of which consist of intracellular regulatory proteins that have traditionally been considered difficult to manipulate using conventional pharmacological approaches. In parallel, rapid progress in RNA engineering has established nucleic acid therapeutics as a versatile approach for precise molecular intervention. Among these, messenger RNA (mRNA) therapeutics are particularly well suited to the molecular landscape emerging from skin aging atlases because they enable transient restoration of proteins that are lost during aging. Advances in lipid nanoparticles, extracellular vesicles and microneedle-based delivery systems are rapidly improving the feasibility of local cutaneous administration. In this review, we discuss the emerging rejuvenation targets identified by single-cell and spatial transcriptomic atlases and examine recent advances in RNA-based therapeutics and mRNA delivery strategies that are paving the way for precision skin rejuvenation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.